Sleep disruption in tetraplegia: a randomised, double-blind, placebo-controlled crossover trial of 3 mg melatonin
Study design: Randomised, double-blind, placebo-controlled crossover trial of melatonin supplementation to people with complete tetraplegia. Objectives: To investigate the effect that 3 mg melatonin supplementation has on objective and subjective sleep, quality of life and mood of people living with...
Gespeichert in:
Veröffentlicht in: | Spinal cord 2014-08, Vol.52 (8), p.629-634 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Study design:
Randomised, double-blind, placebo-controlled crossover trial of melatonin supplementation to people with complete tetraplegia.
Objectives:
To investigate the effect that 3 mg melatonin supplementation has on objective and subjective sleep, quality of life and mood of people living with complete tetraplegia.
Setting:
Austin Hospital Sleep Laboratory and participants’ homes, Melbourne, Victoria, Australia.
Methods:
Two week run-in followed by 3 week nightly administration of 3 mg melatonin or placebo, 2-week washout and further 3 week administration of the opposite treatment. Four testing sessions were conducted; the last nights of the run-in, treatment and washout periods. Testing sessions involved recording full polysomnography, completing a questionnaire battery and collecting urine and blood samples. The questionnaires assessed mood, sleep symptoms and health-related quality of life, and the urine and plasma samples assayed 6-sulphatoxymelatonin (aMT6s) and melatonin levels, respectively. A sleep diary was completed throughout the study.
Results:
Eight participants (mean (s.d.): age 49.5 years (16), postinjury 16.9 years (7.1)) were recruited in which seven concluded the protocol. Endogenous-circulating melatonin was significantly higher (
P
⩽0.01) following melatonin (urine: 152.94 μg h
−1
(74.51), plasma: 43 554.57 pM (33 527.11)) than placebo (urine: 0.86 μg h
−1
(0.40), plasma: 152.06 pM (190.55)). Subjective sleep improved significantly following melatonin specifically for duration of sleep per night and psychological wellbeing. Objective sleep showed a significant increase in light sleep with melatonin, with all other sleep parameters being unchanged.
Conclusion:
These results suggest that increasing melatonin in people with complete tetraplegia is beneficial, especially for subjective sleep. Investigation of the pharmacokinetics of melatonin metabolism in this population is warranted.
Sponsorship:
This project is proudly supported by the Transport Accident Commission. |
---|---|
ISSN: | 1362-4393 1476-5624 |
DOI: | 10.1038/sc.2014.84 |